Canbex Therapeutics

Canbex Therapeutics, Ltd. is a London-based company focused on developing peripherally-acting cannabinoid agonists aimed at treating spasticity associated with multiple sclerosis and other neurodegenerative diseases. Founded in 2005, the company addresses the debilitating symptoms of spasticity, which include involuntary muscle spasms and stiffness. Canbex Therapeutics strives to enhance the quality of life for individuals suffering from this serious and often incurable condition, with the objective of establishing a new standard in the treatment of spasticity.